Interleukin 2 low dose (Beijing ShuangLu Pharmaceutical)

N/A

Report date: 2022/12/03 20:00:24

Base Information

Drug NameInterleukin 2 low dose (Beijing ShuangLu Pharmaceutical)
Drug Alias NamehrIL-2
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor agonistsRegulatory T-lymphocytes stimulants
TargetsInterleukin-2 receptor
Therapy Area/IndicationsMacrophage Activation SyndromeLupus Erythematosus, SystemicSjogren-Larsson Syndrome +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing Sl Pharmaceutical Co LtdPeking University People'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPeking University People'S Hospital
Inactive CompaniesBeijing Sl Pharmaceutical Co Ltd
Active IndicationsLupus Erythematosus, SystemicSjogren-Larsson SyndromeDermatomyositis +[5] 
Inactive IndicationsMacrophage Activation SyndromePolymyalgia RheumaticaMyositis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A